Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.

Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.

Item
http://www.wikidata.org/entity/Q42251464
Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Access to substance use treatment among young adults who use prescription opioids non-medically.Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.Instrumental support to facilitate hepatitis C treatment adherence: working around shortfalls in shared-care.Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion.Families Living with Blood-Borne Viruses: The Case for Extending the Concept of "Serodiscordance".Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments.Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia
P2860

Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.

Item
http://www.wikidata.org/entity/Q42251464
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Barriers and facilitators for ...... insights from the ETHOS study.
@en
Barriers and facilitators for ...... insights from the ETHOS study.
@nl
type
label
Barriers and facilitators for ...... insights from the ETHOS study.
@en
Barriers and facilitators for ...... insights from the ETHOS study.
@nl
prefLabel
Barriers and facilitators for ...... insights from the ETHOS study.
@en
Barriers and facilitators for ...... insights from the ETHOS study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Barriers and facilitators for ...... insights from the ETHOS study.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921